Temporal Patterns of Antithrombotic Therapy and Clinical Outcomes After Atrial Fibrillation-Related Stroke
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
There is clinical equipoise in relation to the optimal timing and strategy for antithrombotic therapy in acute ischemic stroke (AIS) patients with atrial fibrillation (AF) who may be eligible for non-vitamin K antagonist oral anticoagulants (NOACs). This study aimed to describe the temporal evolution of antithrombotic treatment strategies and associated clinical outcomes after AF-related AIS.
Methods
This multicenter prospective cohort study enrolled 2,965 patients with AIS and AF from 16 tertiary stroke centers across South Korea between February 2018 and January 2021, with follow-up completed by January 2022. The primary outcome was a composite of recurrent stroke, myocardial infarction, and all-cause death. Secondary outcomes included individual components of the primary outcome and major bleeding events.
Results
The median follow-up duration was 1.92 years. Among 2,965 patients (mean [SD] age, 75.3 [10.2] years; 54.1% male), antithrombotic strategies varied widely in the acute phase. Within 48 hours of admission, 50.9% received antiplatelet-only therapy (29.4% single, 21.5% dual), 23.2% received NOAC monotherapy, and 10.4% received a combination of antiplatelets and anticoagulants. By discharge, NOAC monotherapy had become the predominant treatment strategy (65.7%), and this pattern persisted throughout follow-up.
This treatment heterogeneity coincided with distinct temporal patterns in clinical outcomes. The incidence of the primary endpoint was highest in the first two weeks (32.70 [95% CI, 29.64-36.06] per 100 person-months), and declined thereafter. Across all time periods, patients receiving NOAC monotherapy consistently had lower incidence rates (3-month rate: 4.95 [95% CI, 4.37-5.61] per 100 person-months) than those receiving antiplatelet-only therapy (11.98 [95% CI, 9.57-15.01]) or no antithrombotic therapy (18.44 [95% CI, 14.26-23.86]).
Conclusions
In this prospective cohort of patients with AF-related stroke, early antithrombotic treatment strategies were heterogeneous but evolved primarily toward use of NOAC monotherapy by the time of discharge from the hospital and during longitudinal follow-up. Treatment selection was associated with marked differences in outcomes, particularly during the early high-risk period. These findings underscore the need for safe and effective, time-sensitive antithrombotic strategies, especially in patients for whom immediate anticoagulation is deferred.
Clinical Perspective
What Is New?
-
This nationwide prospective cohort study evaluated temporal trends in antithrombotic therapy and outcomes in patients with atrial fibrillation (AF)-related ischemic stroke.
-
There was substantial heterogeneity in early treatment strategies, which converged toward NOAC (non–vitamin K antagonist oral anticoagulant) monotherapy by discharge.
-
The risk of recurrent vascular events and death was highest during the first 2 weeks post-stroke and varied significantly by antithrombotic regimen.
What Are the Clinical Implications?
-
The early post-stroke period represents a critical window with elevated risk and variable treatment practices.
-
NOAC monotherapy was consistently associated with the lowest event rates, supporting early initiation when feasible.
-
Timely and individualized antithrombotic strategies are essential to improve outcomes, especially for patients in whom anticoagulation is initially deferred.
